Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 978 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: metformin Clear all
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Metformin on AD Biomarkers

NCT01965756
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

NCT01068730
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
metformin (Diabex), metformin (Glucophage™)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 21, 2026, 4:57 AM EDT
Terminated Phase 3 Interventional Results available

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

NCT02932475
View directory record Official record
Conditions
Diabetes, Pregnancy
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Improve PAD PERformance With METformin

NCT03054519
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Metformin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
5
States / cities
Gainesville, Florida • Chicago, Illinois • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

NCT01454622
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

NCT01376557
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
75 mg LX4211, 200 mg LX4211, 400 mg LX4211, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
56
States / cities
Anaheim, California • Carmichael, California • Greenbrae, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 21, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

Effects of Metformin on Low Back Pain

NCT04055012
View directory record Official record
Conditions
Low Back Pain
Interventions
Metformin, Placebo
Drug
Lead sponsor
Gwendolyn Sowa
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

NCT01750567
View directory record Official record
Conditions
Relapsed Chronic Lymphocytic Leukemia
Interventions
Metformin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

NCT02035787
View directory record Official record
Conditions
Complex Atypical Hyperplasia, Endometrial Cancer
Interventions
Metformin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin

NCT02135549
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SugarDown, Placebo Oral Tablet
Dietary Supplement · Drug
Lead sponsor
Boston Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Garden City, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

EMPOWIR:Enhance the Metabolic Profile of Women With Insulin Resistance

NCT00618072
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Obesity
Interventions
metformin and rosiglitazone
Drug
Lead sponsor
New York Medical College
Other
Eligibility
35 Years to 55 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2014 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

NCT02305381
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
72
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

NCT00396357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Vildagliptin, metformin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 78 Years
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Effect of PF-00734200 in Subjects With Type 2 Diabetes

NCT00618007
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-00734200 30 mg QD, PF-00734200 20 mg QD, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Litchfield Park, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

NCT01192152
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 2 Interventional

Safety Study of BMS-823778 in Subjects With Type 2 Diabetes

NCT01111955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BMS-823778, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Hialeah, Florida • Olympia, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Results available

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2, PF-04937319 MR 3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
High Point, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 21, 2026, 4:57 AM EDT
Completed Phase 3 Interventional Results available

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

NCT02022007
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Interventions
Metformin XR, Saxagliptin, Saxagliptin-Metformin XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 21, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

NCT02969798
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions
Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 4:57 AM EDT